Shanghai Henlius Biotech Inc., a biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 2696), has reported its financial results for the first half of 2024, with a 9.8% year-on-year (YOY) increase in revenue, amounting to RMB 2.7461 billion. The company has sustained profitability, building on its first profitable year in 2023, and has reported a net profit of RMB 386.3 million, which is a 61.0% YOY increase.
Henlius has made significant strides in product commercialization, launching six products in China and securing global approvals for three of them, with 24 indications approved across 48 countries and regions, benefiting approximately 600,000 patients. Core commercialized products have contributed to sales of RMB 2.4794 billion, a 15.2% YOY increase. Notably, Hanquyou (trastuzumab biosimilar, HLX02), the anti-PD-1 inhibitor HanSiZhuang (serplulimab, HLX10), and Hanbeitai (bevacizumab biosimilar) have achieved sales of RMB 1.4743 billion (+15.5%), RMB 6.778 billion (+21.8%), and RMB 86.7 million, respectively.
Adhering to a differentiated innovation strategy, Henlius continues to expand and refine its product pipeline. The reported R&D expenses for the period were RMB 825.6 million, marking an increase from the RMB 673.8 million spent in the same period last year. By the end of the reporting period, the company had developed a robust portfolio of over 50 molecules and 14 R&D platforms, encompassing monoclonal antibodies, multi-specific antibodies, antibody drug conjugates, fusion proteins, and small molecule drugs. In terms of late-stage development, the marketing filing for HLX14 (denosumab biosimilar) in the European Union was accepted in May 2024, with approval anticipated in 2025. Henlius also plans to submit marketing authorization applications for HLX14 in the United States and HLX11 (a biosimilar of pertuzumab) in both China and the United States in the latter half of 2024.- Flcube.com
